Treatment News : Another Study Suggests PrEP Doesn’t Lead to Riskier Sex

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » January 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


January 8, 2014

Another Study Suggests PrEP Doesn’t Lead to Riskier Sex

Taking Truvada (emtricitabine/tenofovir) as pre-exposure prophylaxis (PrEP) did not lead HIV-negative people in a large study to take increased sexual risks, although there are caveats to these findings, Reuters reports. Approved in 2012 as an HIV prevention tool that can reduce the risk of transmission by more than 90 percent if used correctly, the antiretroviral has remained controversial, and sparsely used, in no small part because of concerns that it will lead to what is known as risk compensation. This phenomenon takes place when an individual responds to an intervention that lowers the risk of a harm by in turn exposing him or herself to greater risk of that harm—in this case, by having more unprotected sex or having sex with greater numbers of partners, for example. Such increased risk-taking could in theory negate the benefit of PrEP and also lead to the spread of other sexually transmitted infections (STIs).

Researchers at the Gladstone Institutes, an affiliate of the University of California, San Francisco, built upon their three-year 2010 Global iPrEx clinical study of Truvada as PrEP. Publishing their findings in PLOS ONE, they re-examined data of the nearly 2,500 HIV-negative gay men and male-to-female transgender women in six countries who participated, looking specifically at those who reported believing that they were not in the half of the study taking the placebo and also that the drug was working.

Theoretically, those who believed to be on an effective HIV prophylaxis therapy would be more inclined toward risk compensation, but the investigators did not find this to be the case. In fact, the group’s behavior trended toward safer-sex practices. The rate of new HIV infections dropped four-fold. The syphilis rate fell as well.

“Our results suggest that HIV prevention strategies such as Truvada don’t result in risk compensation because they provide an opportunity for participants to actively engage in and reduce their risk of HIV infection,” Gladstone Institutes’ Robert Grant, MD, MPH, who led the research team, said in a release. “Engagement, which also includes counseling, provision of condoms and management of other sexually transmitted infections, leads to motivation, which comes at a time when motivation for preventing new HIV infections is vital to curbing the spread of this worldwide epidemic.”
A significant caveat of these findings is that they are not taken from a real-world sample. It remains to be seen how risk compensation may play out in the large-scale use of PrEP among populations not under the close watch of a clinical trial.

To read the Reuters story, click here.

To read a release on the study, click here.

Search: PrEP, HIV, pre-exposure prophylaxis, Truvada, emtriciatbine, tenofovir, prevention, transmission, sexually transmitted infections, syphilis, Global iPrEx, Gladstone Institues, Robert Grant, PLOS ONE, risk compensation.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (2 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Do you ever have problems sleeping?

Lean On Me

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2015 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.